These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 25632852)

  • 1. Association between skin and joint involvement in patients with psoriatic arthritis treated with adalimumab: analysis of data from a German non-interventional study.
    Thaçi D; Behrens F; Greger G; Burkhardt H; Gnann H; Schopf R; Wittig BM
    Dermatology; 2015; 230(3):213-21. PubMed ID: 25632852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study.
    Gladman DD; ; Sampalis JS; Illouz O; Guérette B
    J Rheumatol; 2010 Sep; 37(9):1898-906. PubMed ID: 20595284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT.
    Mease PJ; Heckaman M; Kary S; Kupper H
    J Rheumatol; 2013 May; 40(5):647-52. PubMed ID: 23504383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial.
    Karanikolas GN; Koukli EM; Katsalira A; Arida A; Petrou D; Komninou E; Fragiadaki K; Zacharioudaki A; Lasithiotakis I; Giavri E; Vaiopoulos G; Sfikakis PP
    J Rheumatol; 2011 Nov; 38(11):2466-74. PubMed ID: 21885499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
    Mease PJ; Gladman DD; Ritchlin CT; Ruderman EM; Steinfeld SD; Choy EH; Sharp JT; Ory PA; Perdok RJ; Weinberg MA;
    Arthritis Rheum; 2005 Oct; 52(10):3279-89. PubMed ID: 16200601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab.
    Borrás-Blasco J; Gracia-Perez A; Nuñez-Cornejo C; Rosique-Robles JD; Mateu-Puchades A; Casterá MD; Rubio-Fabra M
    J Clin Pharm Ther; 2008 Jun; 33(3):321-5. PubMed ID: 18452420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestations.
    Van den Bosch F; Kavanaugh A; Kron M; Kupper H; Mease PJ
    J Rheumatol; 2015 Jun; 42(6):952-9. PubMed ID: 25834212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
    Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
    Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
    Genovese MC; Mease PJ; Thomson GT; Kivitz AJ; Perdok RJ; Weinberg MA; Medich J; Sasso EH;
    J Rheumatol; 2007 May; 34(5):1040-50. PubMed ID: 17444593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
    J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
    Kirson NY; Rao S; Birnbaum HG; Kantor E; Wei RS; Cifaldi M
    J Med Econ; 2013; 16(4):479-89. PubMed ID: 23339434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials.
    Mease PJ; Signorovitch J; Yu AP; Wu EQ; Gupta SR; Bao Y; Mulani PM
    Dermatology; 2010; 220(1):1-7. PubMed ID: 19940437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, randomized, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on lesional and nonlesional skin.
    de Groot M; Picavet DI; van Kuijk AW; Tak PP; Bos JD; de Rie MA; Teunissen MB
    Dermatology; 2012; 225(4):298-303. PubMed ID: 23257348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52.
    Smolen JS; Mease P; Tahir H; Schulze-Koops H; de la Torre I; Li L; Hojnik M; Sapin C; Okada M; Caporali R; Gratacós J; Goupille P; Liu Leage S; Pillai S; Nash P
    Ann Rheum Dis; 2020 Oct; 79(10):1310-1319. PubMed ID: 32660977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
    Mease PJ; Smolen JS; Behrens F; Nash P; Liu Leage S; Li L; Tahir H; Gooderham M; Krishnan E; Liu-Seifert H; Emery P; Pillai SG; Helliwell PS;
    Ann Rheum Dis; 2020 Jan; 79(1):123-131. PubMed ID: 31563894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of adalimumab therapy on musculoskeletal manifestations and health-related quality of life in patients with active psoriatic arthritis.
    Tsuji S; Higashiyama M; Inaoka M; Tomita T; Yokomi A; Satoh A; Hirano A; Hayashi M; Tsuji M; Kunugiza Y; Hamada M; Yoshikawa H
    Mod Rheumatol; 2013 May; 23(3):529-37. PubMed ID: 22752535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study.
    Behrens F; Koehm M; Arndt U; Wittig BM; Greger G; Thaçi D; Scharbatke E; Tony HP; Burkhardt H
    J Rheumatol; 2016 Mar; 43(3):632-9. PubMed ID: 26669916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up.
    Vogelzang EH; Kneepkens EL; Nurmohamed MT; van Kuijk AW; Rispens T; Wolbink G; Krieckaert CL
    Ann Rheum Dis; 2014 Dec; 73(12):2178-82. PubMed ID: 25115447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions.
    Van den Bosch F; Manger B; Goupille P; McHugh N; Rødevand E; Holck P; van Vollenhoven RF; Leirisalo-Repo M; Fitzgerald O; Kron M; Frank M; Kary S; Kupper H
    Ann Rheum Dis; 2010 Feb; 69(2):394-9. PubMed ID: 19815494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.